FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
The FDA has granted priority review status for Otsuka Pharmaceutical's NDA for Simtriyo, containing centanafadine.
Asset / Drug
Drug and asset intelligence for Simtriyo with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.